Stay updated with breaking news from Nasdaq Fold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Finepoint Capital LP cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,428,475 shares of the biopharmaceutical company’s stock after selling 259,925 shares during the quarter. Amicus Therapeutics […]
Sectoral Asset Management Inc. lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 11.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 507,682 shares of the biopharmaceutical company’s stock after selling 65,000 shares during the […]
StockNews.com began coverage on shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) in a report published on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. The Goldman Sachs Group increased their price target on Amicus Therapeutics from $10.00 to […]
Equities researchers at StockNews.com assumed coverage on shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) in a research note issued on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock. Several other research firms have also recently commented on FOLD. The Goldman Sachs Group lifted their target price on shares of Amicus […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) – Equities researchers at SVB Leerink cut their Q2 2023 earnings estimates for Amicus Therapeutics in a research note issued to investors on Wednesday, May 10th. SVB Leerink analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, down […]